SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-004660
Filing Date
2024-02-02
Accepted
2024-02-02 08:30:27
Documents
20
Period of Report
2024-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 60849
2 ex10-1.htm EX-10.1 15482
3 ex10-2.htm EX-10.2 16028
4 ex10-3.htm EX-10.3 16528
5 ex10-4.htm EX-10.4 65812
6 ex10-5.htm EX-10.5 66409
7 ex10-6.htm EX-10.6 72467
  Complete submission text file 0001493152-24-004660.txt   533757

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE rspi-20240130.xsd EX-101.SCH 3018
9 XBRL LABEL FILE rspi-20240130_lab.xml EX-101.LAB 34240
10 XBRL PRESENTATION FILE rspi-20240130_pre.xml EX-101.PRE 22361
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3300
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 24588893
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)